• Publications
  • Influence
Impact of armed conflicts and warfare on opioid substitution treatment in Ukraine: responding to emergency needs.
Ukraine has one of the highest HIV prevalences in the astern Europe (Bojko, Dvoriak, & Altice, 2013; Corsi et al., 014; Degenhardt et al., 2014; Kiriazova, Postnov, Perehinets, & eduzhko, 2013;Expand
  • 11
  • 2
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
BACKGROUND Coverage with opioid agonist treatments (OAT) that include methadone and buprenorphine is low (N=8400, 2.7%) for the 310,000 people who inject drugs (PWID) in Ukraine. In the context ofExpand
  • 21
  • 1
Integrated opioid substitution therapy and HIV care: a qualitative systematic review and synthesis of client and provider experiences
ABSTRACT People who use drugs in many contexts have limited access to opioid substitution therapy and HIV care. Service integration is one strategy identified to support increased access. We reviewedExpand
  • 14
  • 1
In their own voices: Breaking the vicious cycle of addiction, treatment and criminal justice among people who inject drugs in Ukraine
Abstract Aims: To understand how perceived law enforcement policies and practices contribute to the low rates of utilisation of opioid agonist therapies (OAT) like methadone and buprenorphine amongExpand
  • 25
Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy
Ukraine's volatile HIV epidemic, one of the largest in Eastern Europe and Central Asia, remains concentrated in people who inject drugs (PWID). HIV prevalence is high (21.3% to 41.8%) among theExpand
  • 22
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Background: The HIV treatment cascade is a crucial tool to guide HIV prevention and treatment strategies. The extent to which opioid agonist treatments (OATs) such as methadone and buprenorphineExpand
  • 9
Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine.
BACKGROUND Scaling up HIV prevention for people who inject drugs (PWID) using opioid agonist therapies (OAT) in Ukraine has been restricted by individual and structural factors. Extended-releaseExpand
  • 8
Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
BACKGROUND HCV prevalence estimates among people who inject drugs (PWID) in Ukraine is high (60-90%), yet barriers to HCV treatment and care remain substantial including limited access to directExpand
  • 10
A qualitative assessment of attitudes about and preferences for extended-release naltrexone, a new pharmacotherapy to treat opioid use disorders in Ukraine.
Numerous individual barriers, including negative attitudes toward opioid agonist therapies (OAT), have undermined HIV prevention efforts in Ukraine where the epidemic is concentrated in people whoExpand
  • 4
Multidrug-resistant tuberculosis in children and adolescents in the WHO European Region: Expert opinion.
Historically, children and adolescents have not been a priority for national programmes for tuberculosis (TB) prevention and care in the WHO European Region. Owing to the low incidence in the RegionExpand
  • 1